Business Context and Reporting Period
This Form 8-K Current Report was filed by Acrivon Therapeutics, Inc. on April 7, 2025. The filing discloses a material corporate event regarding executive leadership changes. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol ACRV.
Key Financial Metrics
This filing is a current report regarding a specific event and does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. No financial data is included in this document.
Material Changes
The primary material change disclosed in this filing is the appointment of new senior management:
- Appointment: Mansoor Raza Mirza, M.D., has been appointed as Chief Medical Officer.
- Effective Date: The appointment is effective as of April 9, 2025.
- Announcement: A press release detailing this appointment is attached as Exhibit 99.1.
Guidance, Outlook, and Risks
This filing does not contain updated financial guidance, forward-looking outlooks, or specific risk factors beyond the standard disclosure language. The information contained in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the professional background and experience of Dr. Mansoor Raza Mirza to assess the strategic impact on the Company's clinical development pipeline.
- Review the attached Press Release (Exhibit 99.1) for any additional context regarding the transition or strategic rationale not detailed in the 8-K summary.
- Confirm the effective date of April 9, 2025, for any internal governance or compensation tracking.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial health metrics.